Renalytix launches new US provider access portal

Renalytix announced the launch of the new ‘myIntelX’ provider access portal on Wednesday, to provide access for United States physicians to order ‘KidneyIntelX’ bioprognostic testing to identify type-2 diabetes patients at the greatest risk of rapid kidney disease progression.

The AIM-traded firm said the portal was being launched in conjunction with the launch of KidneyIntelX testing within Atrium Health, which previously announced a collaboration with Renalytix in May 2021.

It said the portal would “streamline” ordering and reporting for current testing locations across the US, including CDPHP health plans in New York state and testing in the Veterans Health Administration (VHA) in Florida.

As part of the regional and VHA expansion for KidneyIntelX, testing was currently live in the Mount Sinai Health System in New York and Wake Forest in North Carolina, and was expected to be implemented within St. Joseph's in New York, Singing River Health System in Mississippi, the University of Utah in Utah, and several additional VHA centres across the country before the end of June.

“Virtual capability provided through our myIntelX portal is an important step towards expanding access nationally to the KidneyIntelX proprietary technology,” said company president Tom McLain.

“MyIntelX now makes simple, early-stage risk assessment available online for practices that might not otherwise have access to KidneyIntelX integrated ordering through our large-scale health system partnerships.”

Renalytix said the launch version of the myIntelX portal would support the “secure and efficient” execution of both test ordering and report delivery of KidneyIntelX.

The portal was designed for scalability, with additional features to support provider and patient education and engagement to follow as part of the fully-integrated KidneyIntelX platform.

After a provider registered with myIntelX, Renalytix said it would enable training and support through its commercial sales and client service teams to implement and sustain testing in independent practices.

Renalytix said it would continue to process all tests through its clinical laboratories.

“There are over 37 million Americans with chronic kidney disease, which can be largely treatable or even preventable, but only when identified and intervened within its early stages,” said chief medical officer Dr Michael Donovan.

“The quality of primary care for patients with chronic kidney disease is impacted by patient volume, comorbidities, geography, and socioeconomic disparities.

“Providing a mechanism that facilitates patient identification, access and monitoring is the first step towards improving overall care.”

At 1211 GMT, shares in Renalytix were up 16.49% at 332p.